Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Oric Pharmaceuticals Inc

Healthcare US ORIC

7.5USD
-0.52(6.48%)

Last update at 2026-06-05T20:01:00Z

Day Range

7.488.12
LowHigh

52 Week Range

4.9916.65
LowHigh

Fundamentals

  • Previous Close 8.02
  • Market Cap593.99M
  • Volume1236300
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-113.05200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.85

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -89.12200M -78.71500M -73.70300M -26.88300M -21.36300M
Minority interest - - - - -
Net income -91.47700M -77.67700M -97.27000M -25.48600M -21.36300M
Selling general administrative 25.09M 22.01M 13.42M 5.72M 3.35M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.97M 0.90M 0.97M 1.03M 0.90M
Ebit -91.76700M -79.76800M -74.18600M -28.56900M -22.37100M
Ebitda -81.76700M -78.87100M -24.50000M -27.54100M -21.46800M
Depreciation and amortization 10.00M 0.90M 49.69M 1.03M 0.90M
Non operating income net other - 0.01M 0.18M - -
Operating income -91.76700M -78.87100M -74.18600M -28.56900M -22.37100M
Other operating expenses 86.77M 78.87M 49.34M 28.57M 22.37M
Interest expense 2.65M 0.14M 0.31M 1.69M 1.01M
Tax provision - - - - -
Interest income 2.65M 0.14M 0.31M 1.40M 0.78M
Net interest income 2.65M 0.14M 0.31M 1.40M 0.78M
Extraordinary items - - - - -
Non recurring -5.00000M - -24.84300M - -
Other items - - - - -
Income tax expense 2.35M -1.03800M 23.57M -1.39700M -1.00800M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 86.77M 78.87M 49.34M 28.57M 22.37M
Cost of revenue - - - - -
Total other income expense net 2.65M 0.16M 0.48M 1.69M 0.23M
Discontinued operations - - - - -
Net income from continuing ops -89.12200M -78.71500M -73.70300M -26.88300M -21.36300M
Net income applicable to common shares -89.12200M -78.71500M -73.70300M -26.88300M -21.36300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 254.69M 247.18M 298.64M 299.00M 94.09M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.41M 4.18M 3.54M 3.10M 0.84M
Total liab 30.60M 24.83M 25.67M 9.22M 6.12M
Total stockholder equity 224.09M 222.35M 272.98M 289.78M 87.97M
Deferred long term liab - - - 0.22M 1.34M
Other current liab 16.76M 11.41M 11.34M 8.24M 5.20M
Common stock 0.00600M 0.00500M 0.00400M 0.00400M 0.00200M
Capital stock 0.00600M 0.00500M 0.00400M 0.00400M 0.00200M
Retained earnings -434.92700M -334.23000M -245.10800M -166.39300M -92.69000M
Other liab - - - 0.22M 0.77M
Good will - - - - -
Other assets - 0.52M 0.52M 0.32M 1.85M
Cash 23.38M 66.84M 226.01M 78.45M 89.16M
Cash and equivalents - - - - -
Total current liabilities 20.46M 15.39M 15.15M 9.00M 5.35M
Current deferred revenue - - - - -
Net debt -13.17100M -64.18100M -224.08000M -78.44600M -89.15900M
Short term debt 2.75M 2.66M 1.93M - -
Short long term debt - - - - -
Short long term debt total 10.21M 2.66M 1.93M - -
Other stockholder equity 658.75M 557.87M 518.18M 157.20M 180.66M
Property plant equipment - 3.25M 2.41M 1.98M 2.24M
Total current assets 212.60M 210.46M 240.52M 296.70M 90.00M
Long term investments 26.85M 21.95M 43.39M - -
Net tangible assets - 222.35M 272.98M 289.78M -90.08400M
Short term investments 184.80M 139.43M 10.97M 215.15M -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.94M 1.32M 1.89M 0.76M 0.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.26M -1.29100M -0.10300M -0.03100M -3.51500M
Additional paid in capital - - - - -
Common stock total equity - 0.00500M 0.00400M 0.00400M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - -334.23000M -245.10800M -166.39300M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.06M 11.52M 12.32M 0.32M 1.85M
Deferred long term asset charges - - - - -
Non current assets total 42.09M 36.72M 58.12M 2.30M 4.09M
Capital lease obligations 2.75M 2.66M 1.93M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -107.17000M 159.37M -215.95900M -215.48500M -0.50800M
Change to liabilities -1.47500M 2.93M 4.30M 0.99M -0.41000M
Total cashflows from investing activities -109.24800M 158.44M -215.95900M -0.76800M -0.50800M
Net borrowings - - - - -
Total cash from financing activities 25.23M 49.13M 250.51M 70.82M 38.01M
Change to operating activities 1.03M 1.14M -2.25800M 0.23M -0.29700M
Net income -89.12200M -78.71500M -73.70300M -26.88300M -21.36300M
Change in cash -159.16600M 148.03M -10.71300M 46.52M 16.82M
Begin period cash flow 226.47M 78.45M 89.16M 42.64M 25.82M
End period cash flow 67.31M 226.47M 78.45M 89.16M 42.64M
Total cash from operating activities -75.14300M -59.54100M -45.26800M -23.53300M -20.68300M
Issuance of capital stock 25.00M 50.00M 271.31M 70.79M 37.93M
Depreciation 0.97M 0.90M 0.97M 1.03M 0.90M
Other cashflows from investing activities - - 0.19M 0.19M 0.02M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - 0.19M - -
Sale purchase of stock 0.55M 50.99M 271.75M 70.92M 38.01M
Other cashflows from financing activities -0.32000M -0.86600M -20.79400M 70.82M 38.01M
Change to netincome 14.50M 12.86M 25.42M 1.10M 0.48M
Capital expenditures 2.08M 0.94M 0.67M 0.77M 0.53M
Change receivables - - - - -
Cash flows other operating 1.03M 1.14M 17.59M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -159.16600M 148.03M -10.71300M - -
Change in working capital -0.44500M 4.07M 2.04M 1.22M -0.70700M
Stock based compensation 14.46M 12.85M 5.28M 1.09M 0.47M
Other non cash items -1.00200M 1.35M 19.84M 0.00800M 0.01M
Free cash flow -77.22100M -60.48000M -45.93500M -24.30100M -21.20800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ORIC
Oric Pharmaceuticals Inc		 -0.52 6.48% 7.50 - - - 2.95 -4.1506
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Oric Pharmaceuticals Inc

240 East Grand Avenue, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Richard A. Heyman Ph.D. Co-Founder, Independent Chairman & Member of Scientific Advisory Board 1957
Dr. Jacob M. Chacko M.B.A., M.D. Pres, CEO & Director 1979
Mr. Dominic G. Piscitelli CPA, CPA, M.B.A. Chief Financial Officer 1975
Dr. Pratik S. Multani M.D., M.S. Chief Medical Officer 1967
Dr. Charles L. Sawyers B.A., BA, M.D., Ph.D. Co-Founder & Member of Scientific Advisory Board 1959
Dr. Scott W. Lowe Ph.D. Co-Founder & Member of Scientific Advisory Board NA
Dr. Lori Sickels Friedman Ph.D. Chief Scientific Officer 1964
Dr. Christian V. Kuhlen Esq., J.D., M.D. Gen. Counsel 1973
Mr. Daniel Iazzetti VP & Head of People NA
Dr. Edna Chow Maneval Sr. VP of Clinical Devel. 1960

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.